RDZN trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes RDZN achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 1 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 30, 2026, Roadzen, Inc. (RDZN) has a Wall Street consensus price target of N/A, based on estimates from 1 covering analysts. The company has a market capitalization of $130M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 1 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, RDZN trades at a trailing P/E of -1.5x. Analysts expect EPS to grow -38.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
HIPOHippo Holdings Inc. | $705M | $27.08 | $28.38 | +4.8% | Buy | 82.1x | 6 |
METCRamaco Resources, Inc. | $689M | $12.68 | $23.33 | +84.0% | Buy | — | 9 |
KINSKingstone Companies, Inc. | $279M | $19.27 | — | — | Buy | 7.4x | 4 |
ROOTRoot, Inc. | $809M | $57.73 | $62.50 | +8.3% | Hold | 18.9x | 14 |
LMNDLemonade, Inc. | $4.8B | $62.18 | $71.00 | +14.2% | Buy | — | 15 |
OSCROscar Health, Inc. | $7.6B | $29.45 | $24.20 | -17.8% | Hold | 28.2x | 11 |
GSHDGoosehead Insurance, Inc | $1.1B | $47.98 | $58.50 | +21.9% | Buy | 21.9x | 18 |
ITICInvestors Title Company | $524M | $277.54 | — | — | — | 45.6x | — |
KVYOKlaviyo, Inc. | $4.5B | $14.93 | $30.88 | +106.8% | Buy | 17.6x | 22 |
GOOGLAlphabet Inc. | $4.3T | $353.65 | $411.80 | +16.4% | Buy | 24.8x | 83 |
Quick answers to the most common questions about buying RDZN stock.
The consensus price target for RDZN is $N/A, close to the current price of $1.54 (N/A% implied move). Based on 1 analyst estimates, the stock appears fairly valued near current levels.
RDZN has a consensus rating of "Buy" based on 1 Wall Street analysts. The rating breakdown is predominantly bullish, with 1 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
RDZN's current price is $1.54 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $N/A for RDZN, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
RDZN is lightly followed, with 1 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month RDZN stock forecast based on 1 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy".
RDZN appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
RDZN analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.